Chromoendoscopy for Invisible Dysplasia in Patients With Inflammatory Bowel Disease

IBD Chromoendoscopy for Invisible Dysplasia in Patients With Inflammatory Bowel Disease IBD Published: October 20, 2026 Key Points Chromoendoscopy detected lesions in 52% of initial referrals for invisible dysplasia, identifying 41% of additional lesions only with this method. Over half of patients (13 out of 23) avoided surgical intervention through long-term chromoendoscopy surveillance.

Surgical pathology in eight patients revealed four high-grade dysplasia cases and one rectosigmoid cancer. Clinical Relevance Chromoendoscopy is a feasible and effective surveillance tool in community practice for patients with IBD and invisible dysplasia. Successful CE-guided management can potentially reduce the need for surgical interventions in over 50% of patients.

Early detection of significant dysplasia and cancer supports individualized, guideline-based IBD surveillance strategies. Editor Reviewed | AI Assisted Abstract Patients with inflammatory bowel disease (IBD) have an increased risk of developing colorectal malignancy compared with the general population.

Therefore, patients with IBD undergo more frequent dysplasia surveillance in order to improve early detection of neoplasia and prevent colorectal cancer. Although most IBD-related dysplasia is visible with modern high-definition (HD) scopes, some dysplasia is still found with random biopsies: so-called invisible dysplasia.